Expert Interviews

Steven Peskin, MD, MBA, FACP, shares perspective on factors that need to be considered by payers when making decisions about how to cover and reimburse for prescription digital therapeutics used to manage behavior-driven conditions.

Current experiences noted by various stakeholders in healthcare regarding the impact of prescription digital therapeutics in clinical practice as tools to help manage patients with behavior-driven conditions, and current limitations that need to be addressed to increase their uptake.

Considerations regarding opportunities to increase payer and provider uptake of prescription digital therapeutics into clinical practice to optimize care for patients with behavior-driven conditions.

Payer and provider insight regarding the potential impact prescription digital therapeutics could have on addressing challenges surrounding the management of behavior-driven conditions.

Nidal Moukaddam, MD, PhD, Baylor College of Medicine, comments on where she sees prescription digital therapeutics being most useful when managing behavior-driven conditions.

Clinicians, a pharmacist, and a payer discuss their current experience with prescription digital therapeutics for behavior-driven conditions and share considerations for expanding on their use in clinical practice.

In this final part of a three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about their focus on social determinants of health and the Covid-19 vaccine.

In this second of a three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization, MLR rates and investing in telehealth models for the better care of its members.

In this first of three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization among its members and the elimination of low-value care.

Thomas P. Leist, MD, PhD, explains that there is no such thing as "one size fits all" for patients with SPMS. Patients can be impacted differently based on how they present themselves and how they behave.

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.

The five states have moved to prohibit accumulators and maximizers as the federal government takes a hands-off approach, according to John “Jack” S. Linehan, a lawyer at Epstein Becker Green, who is featured in this second part of a two-part video series.

Thomas P. Leist, MD, PhD, says doctors working with patients diagnosed with SPMS don't necessarily have prognostic biomarkers to detect SPMS. The best prognostic biomarkers they have currently are MRI and potentially neurofilament light. He adds their techniques need to improve in order to harness the full benefit of potentially individualizing care to the most optimal fashion in a given patient.

John “Jack” S. Linehan, a lawyer at Epstein Becker Green, is featured in the first part of a two-part video series on copay accumulators and maximizers.

Thomas P. Leist, MD, PhD, discusses secondary progressive MS, more specifically how very early control of the disease gives the patient the best chance for long term stability and gives the patient, the best chance of not entering the secondary state.

Fred Lublin, MD, says it's possible health professionals can develop some biomarkers and find some differences in advanced MRI metrics in finding Secondary Progressive Multiple Sclerosis.

In this second of a two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says he is in favor of extending CMS waivers that made telehealth visits reimbursable and easy for patients and providers.

In this first of two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says the Boston-based telehealth company typically white labels its software to a client’s brand.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.